• Jun-ichi Kadota
Part of the Progress in Inflammation Research book series (PIR)


Cystic Fibrosis Macrolide Antibiotic Human Bronchial Epithelial Cell Neutrophil Chemotaxis Lower Respiratory Tract Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M (1998) Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 157: 1829–32PubMedGoogle Scholar
  2. 2.
    Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J (2002) Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomized trial. Thorax 57: 212–16CrossRefPubMedGoogle Scholar
  3. 3.
    Scboni MH (2003) Macrolide antibiotic therapy in patients with cystic fibrosis. Swiss Med Wkly 133: 297–301PubMedGoogle Scholar
  4. 4.
    Kadota J, Sakito O, Kohno S, Sawa H, Mukae H, Oda H, Kawakami K, Fukushima K, Hiratani K, Hara K (1993) A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis 147: 153–9PubMedGoogle Scholar
  5. 5.
    Fujii T, Kadota J, Kawakami K, Iida K, Shirai R, Kaseda M, Kawamoto S, Kohno S (1995) Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax 50: 1246–52PubMedGoogle Scholar
  6. 6.
    Oda H, Kadota J, Kohno S, Hara K (1994) Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis. Chest 106: 1116–23PubMedGoogle Scholar
  7. 7.
    Sakito O, Kadota J, Kohno S, Abe K, Shirai R, Hara K (1996) Interleukin 1β, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: A potential mechanism of macrolide therapy. Respiration 63: 42–8PubMedGoogle Scholar
  8. 8.
    Fujii T, Kadota J, Morikawa T, Matsubara Y, Kawakami K, Iida K, Shirai R, Taniguchi H, Kaseda M, Kawamoto K et al (1996) Inhibitory effect of erythromycin on interleukin-8 production by 1α,25-dihydroxyvitamin D3-stimulated THP-1 cells. Antimicrob Agents Chemother 40: 1548–51PubMedGoogle Scholar
  9. 9.
    Oishi K, Sonoda F, Kobayashi S, Iwagaki A, Nagatake T, Matsushima K, Matsumoto K (1994) Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect Immun 62: 4145–52PubMedGoogle Scholar
  10. 10.
    Khair OA, Devalia JL, Abdelaziz MM, Sapsford RJ, Davies RJ (1995) Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells. Eur Respir J 8: 1451–7PubMedGoogle Scholar
  11. 11.
    Oda H, Kadota J, Kohno S, Hara K (1995) Leukotriene B4 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Chest 108: 116–22PubMedGoogle Scholar
  12. 12.
    Scaglione F, Rossoni G (1998) Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin. J Antimicrob Chemother 41: 47–50CrossRefGoogle Scholar
  13. 13.
    Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombola L, Carnuccio R, Iuvone T, D’Acquisto F, Di Rosa M (2000) Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 292: 156–63PubMedGoogle Scholar
  14. 14.
    Kawashima M, Yatsunami J, Fukuno Y, Nagata M, Tominaga M, Hayashi S (2002) Inhibitory effects of 14-membered ring macrolide antibiotics on bleomycin-induced acute lung injury. Lung 180: 73–89PubMedGoogle Scholar
  15. 15.
    Kusano S, Kadota J, Kohno S, Iida K, Kawakami K, Morikawa T, Hara K (1995) Effect of roxithromycin on peripheral neutrophil adhesion molecules in patients with chronic lower respiratory tract disease. Respiration 62: 217–22PubMedGoogle Scholar
  16. 16.
    Kawasaki S, Takizawa H, Ohtoshi T, Takeuchi N, Kohyama T, Nakamura H, Kasama T, Kobayashi K, Nakahara K, Morita Y et al (1998) Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells in vitro. Antimicrob Agents Chemother 42: 1499–502PubMedGoogle Scholar
  17. 17.
    Li Y, Azuma A, Takahashi S, Usuki J, Matsuda K, Aoyama A, Kudoh S (2002) Fourteen-membered ring macrolides inhibit vascular cell adhesion molecule 1 messenger RNA induction and leukocyte migration. Chest 122: 2137–45CrossRefPubMedGoogle Scholar
  18. 18.
    Anderson R (1989) Erythromycin and roxithromycin potentiate human neutrophil locomotion in vitro by inhibition of leukoattractant-activated superoxide generation and autooxidation. J Infect Dis 159: 966–73PubMedGoogle Scholar
  19. 19.
    Labro MT, Amit N, Babin-Chevaye C, Hakim J (1986) Synergy between RU 28965 (roxithromycin) and human neutrophils for bactericidal activity in vitro. Antimicrob Agents Chemother 30: 137–42PubMedGoogle Scholar
  20. 20.
    Hojo M, Fujita I, Hamasaki Y, Miyazaki M, Miyazaki S (1994) Erythromycin does not directly affect neutrophil functions. Chest 105: 520–3PubMedGoogle Scholar
  21. 21.
    Brennan S, Cooper D, Sly PD (2001) Directed neutrophil migration to IL-8 is increased in cystic fibrosis: a study of the effect of erythromycin. Thorax 56: 62–4CrossRefPubMedGoogle Scholar
  22. 22.
    Torre D, Broggini M, Botta V, Sampietro C, Busarello R, Garberi C (1991) In vitro and ex vivo effects of recent and new macrolide antibiotics on chemotaxis of human polymorphonuclear leukocytes. J Chemother 3: 236–9PubMedGoogle Scholar
  23. 23.
    Anderson R, Fernandes AC, Eftychis HE (1984) Studies on the effects of ingestion of a single 500 mg oral dose of erythromycin stearate on leukocyte motility and transformation and on release in vitro of prostaglandin E2 by stimulated leucocytes. J Antimicrob Chemother 14: 41–50PubMedGoogle Scholar
  24. 24.
    Burgaleta C, Moreno T (1987) Effect of beta-lactams and aminoglycosides on human polymorphonuclear leucocytes. J Antimicrob Chemother 20: 529–35PubMedGoogle Scholar
  25. 25.
    Labro MT, Babin-Chevaye C, Hakim J (1986) Effects of cefotaxime and cefodizime on human granulocyte functions in vitro. J Antimicrob Chemother 18: 233–7PubMedGoogle Scholar
  26. 26.
    Van Rensburg CE, Anderson R, Eftychis HA, Joone GK (1983) Effects of cefotaxime on neutrophil and lymphocyte functions. S Afr Med J 64: 346–8PubMedGoogle Scholar
  27. 27.
    Gialdroni Grassi G, Fietta A, Sacchi F, Derose V (1984) Influence of ceftriaxone on natural defense systems. Am J Med 77: 37–41Google Scholar
  28. 28.
    Moran FJ, Puente LF, Perez-Giraldo C, Hurtado C, Blanco MT, Gomez-Garcia AC (1994) Effects of cefpirome in comparison with cefuroxime against human polymorphonuclear leucocytes in vitro. J Antimicrob Chemother 33: 57–62PubMedGoogle Scholar
  29. 29.
    Fietta A, Merlini C, Gialdroni Grassi G (1994) In vitro activity of two new oral cephalosporins, cefixime and cefdinir (CI 983), on human peripheral mononuclear and polymorphonuclear leukocyte functions. Chemotherapy 40: 317–23PubMedGoogle Scholar
  30. 30.
    Cornacchione P, Scaringi L, Capodicasa E, Fettucciari K, Rosati E, Sabatini R, Benedetti C, Marconi P, Rossi R, Del Favero A (2000) In vitro effects of meropenem and imipenem/cilastatin on some functions of human natural effector cells. Chemotherapy 46: 135–42CrossRefPubMedGoogle Scholar
  31. 31.
    Venezio FR, DiVincenzo CA (1985) Effects of aminoglycoside antibiotics on polymorphonuclear leukocyte function in vivo. Antimicrob Agents Chemother 27: 712–14PubMedGoogle Scholar
  32. 32.
    Delfino D, Bonina L, Berlinghieri MC, Mastroeni P (1985) Effects of a new quinoline derivative, ciprofloxacin, on some professional phagocytic cell functions. Chemioterapia 4: 463–6PubMedGoogle Scholar
  33. 33.
    Grassi GG, Fietta A (1991) Antibiotics and their interaction with the host defense system in vivo. J Chemother 3(Suppl 1): 112–15PubMedGoogle Scholar
  34. 34.
    Sugita K, Nishimura T (1995) Effect of antimicrobial agents on chemotaxis of polymorphonuclear leukocytes. J Chemother 7: 118–25PubMedGoogle Scholar
  35. 35.
    Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW 3rd; Macrolide Study Group (2003) Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290: 1749–56CrossRefPubMedGoogle Scholar
  36. 36.
    Yamada T, Fujieda S, Mori S, Yamamoto H, Saito H (2000) Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage. Am J Rhinol 14: 143–8PubMedGoogle Scholar
  37. 37.
    Nakamura H, Fujishima S, Inoue T, Ohkubo Y, Soejima K, Waki Y, Mori M, Urano T, Sakamaki F, Tasaka S et al (1999) Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur Respir J 13: 1371–9PubMedGoogle Scholar
  38. 38.
    Komiyane M, Tokura S, Matsunaga Y, Akamatsu H, Tamaoki K (2000) Symposium 2: Novel activities of macrolides in dermatology. Jpn J Antibiot 54(Supp. A): 100–12Google Scholar
  39. 39.
    Mikamo H, Kawazoe K, Sato Y, Tamaya T (1998) Effects of long-term/low-dose clarithromycin on neutrophil count and interleukin-8 level in pyometra. Chemotherapy 44: 50–4CrossRefPubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 2005

Authors and Affiliations

  • Jun-ichi Kadota
    • 1
  1. 1.Division of Pathogenesis and Disease Control Department of Infectious DiseasesOita University Faculty of MedicineOitaJapan

Personalised recommendations